News | December 31, 2024
Senores Pharmaceuticals IPO lists at 53% premium
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Cenexi is committed to working closely with the ANSM to address the observations
Karkinos is in the business of providing technology-driven, innovative solutions for the early detection, diagnosis, and management of cancer.
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
Zydus Lifesciences and SBL have mutually decided to extend the date of closing upto March 31, 2025
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Alankit will undertake the verification of pending e-KYC enrollments through the Beneficiary Identification System (BIS) platform provided by the National Health Authority (NHA).
Subscribe To Our Newsletter & Stay Updated
